A novel role for a familiar protein in apoptosis induced by proteasome inhibition.

Abstract

In this issue of Cancer Cell, Nickeleit et al. (2008) identify a new proteasome inhibitor, argyrin A, and show that it induces apoptosis and inhibits angiogenesis via p27-dependent mechanisms. Their observations challenge current thinking about how this class of promising cancer therapies works and why they selectively kill cancer cells.

• Authors: David J McConkey
• Journal: Cancer cell (Cancer Cell) Vol. 14 Issue 1 Pg. 1-2 (Jul 08 2008) ISSN: 1878-3686 [Electronic] United States
• PMID: 18598936 (Publication Type: Comment, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Boronic Acids
• CDKN1B protein, human
• Cysteine Proteinase Inhibitors
• Intracellular Signaling Peptides and Proteins
• Proteasome Inhibitors
• Pyrazines
• Cyclin-Dependent Kinase Inhibitor p27
• Bortezomib
• Proteasome Endopeptidase Complex

Topics

• Angiogenesis Inhibitors (pharmacology, therapeutic use)
• Animals
• Apoptosis (drug effects)
• Blood Vessels (drug effects, pathology)
• Boronic Acids (pharmacology)
• Bortezomib
• Cell Cycle (drug effects)
• Cell Proliferation (drug effects)
• Cyclin-Dependent Kinase Inhibitor p27
• Cysteine Proteinase Inhibitors (pharmacology, therapeutic use)
• Dose-Response Relationship, Drug
• Humans
• Intracellular Signaling Peptides and Proteins (metabolism)
• Necrosis
• Neoplasms (blood supply, drug therapy, enzymology, pathology)
• Neovascularization, Pathologic (enzymology, prevention & control)
• Proteasome Endopeptidase Complex (genetics, metabolism)
• Proteasome Inhibitors
• Protein Processing, Post-Translational (drug effects)
• Pyrazines (pharmacology)
• Time Factors
• Up-Regulation